Axtria Presents Two HEOR/RWE Studies at ISPOR Europe 2022 - StreetInsider.com
Overview
FRE Breaking News Alerts from StretInsider.com! StretInsider.com Top Tickers, 1/3/202Research Findings Showcase How Diferent HEOR Modeling Methods Combined with RWD/RWE Are Taking the Industry’s Conversations with the Payers to the Next LevelViena, Austria, Nov. 03, 2022 (GLOBE NEWSWIRE) - Axtria, a global cloud software, integrated RWE/HEOR analytics solutions provider, and AI/ML technology leader for the life sciences industry, wil present two posters at this year’s ISPOR Europe 2022 conference that combine diferent modeling methods with the latest advanced analytics technologies.
Key Information
Both wil highlight the clinical and economic benefits of anti-arhythmic drugs (ADs) for treating atrial fibrilation (AFib) as wel as glargine insulin for treating type 2 diabetes. The poster findings underscore Axtria’s work leading the evolution of advanced data analytics and inteligent software technology in the aplication of diferent real world evidence (RWE) research into advanced value-based models.
Axtria’s latest thought leadership in this area, a white paper titled “Seing the Whole Elephant: Integrated Data Analytics in Suport of RWE” adreses the emergence of integrated RWE/HEOR analytics. This white paper can be found in Axtria’s Research Hub. The first Axtria poster, Clinical and Economic Outcomes associated with Use of Anti-Arhythmic Drugs Versus Ablation in Atrial Fibrilation (AFib), to be presented on Monday, November 7 at 15:0 (CET), utilizes a modeling aproach caled Rhythm Control to demonstrate the cost benefits of ADs compared to ablation as a treatment for AFib.
Summary
The second Axtria poster, The Economic Value of Insulin Glargine 30 U/Ml (GLA-30) in People ≥18 Years of Age with Type 2 Diabetes Melitus: A Value-Based Economic Model from a U.S. Payer Perspective, to be presented on Tuesday, November 8 at 15:0 (CET), uses another aproach caled prevalence-based value-based modeling to demonstrate the value and afordability of the insulin biosi
Frequently Asked Questions
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
Share this article